are you saying NVS reported $170 million while MNTA will report $200-$225 million for Q4?
No, of course not. MNTA’s Lovenox profit share is derived from NVS’ sales to wholesalers/distributors, not from wholesalers/distributors’ sales to end users.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”